Kynam Capital reports 5.27% stake in Sutro Biopharma (NASDAQ: STRO)
Rhea-AI Filing Summary
Sutro Biopharma, Inc. Schedule 13G/A shows 872,558 shares of Common Stock were reported beneficially owned, representing 5.27% of the class as disclosed with a 03/31/2026 reference. The ownership is reported by Kynam Capital Management entities and Yue Tang, each with shared voting and dispositive power over the same 872,558 shares.
Positive
- None.
Negative
- None.
Insights
Institutional holder reports a 5.27% shared stake in Sutro Biopharma.
The filing lists 872,558 shares as beneficially owned with 5.27% of the class as of 03/31/2026. The position is reported across Kynam Capital Management, Kynam Capital Management GP, LLC, and Yue Tang, each shown with shared voting and dispositive power over the same shares.
Cash‑flow treatment is not stated in the excerpt; subsequent filings would show any trades or disposals. The ownership is a disclosure of position size rather than a transaction-oriented filing.
Disclosure emphasizes shared authority rather than sole control over the reported shares.
The Schedule 13G/A attributes 872,558 shares to shared voting and shared dispositive power for the listed filers. Signatures bear a 05/15/2026 signing date in the excerpt.
Filing indicates beneficial ownership reporting obligations were met; any change in voting or disposition authority would require updated disclosure in future filings.
Key Figures
Key Terms
beneficially owned regulatory
Schedule 13G/A regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.